SES
3.11.2020 08:52:12 CET | Business Wire | Press release
SES today announced Gilat and ST Engineering iDirect as its latest technology partners who will be developing the core infrastructure modem platforms for O3b mPOWER , SES’s ground-breaking non-geostationary-satellite orbit (NGSO) communications system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102006117/en/
Gilat and ST Engineering iDirect were selected based on their next-generation modem technologies. Featuring open architectures with a path to full virtualisation, the modems will interface with SES’s differentiated Adaptive Resource Control (ARC) capability and leverage SES’s use of the Open Networking Automation Platform (ONAP) standard. The combination of this and other technologies will give SES the ability to dynamically control and optimise the entire O3b mPOWER system across space and ground infrastructure, enabling the efficient delivery of low-latency and high-throughput satellite-based data services that can be truly customised to fit specific connectivity requirements on land, at sea or in the air anywhere in the world.
O3b mPOWER is SES’s next-generation medium Earth orbit (MEO) communications system. It is currently under construction and on track for launch in 2021. The high-throughput satellites, as well as automated and intelligence-powered ground infrastructure, will deliver low-latency managed services from hundreds of Mbps up to multiple Gbps.
"We are honoured to have been selected by SES, our long-time strategic partner, to provide our next-generation baseband platform for O3b mPOWER. Gilat's innovative ground segment significantly reduces cost-per-bit, delivers a step-change in modem performance, and further integrates with and optimises SES ground and space service delivery," said Ron Levin Vice President Mobility and Global Accounts at Gilat. "Throughout the last year, we have been working closely with SES to develop the platform for O3b mPOWER with the joint goal of bringing to market unparalleled customer experience in all target verticals.”
“We are at the beginning of a new future for our industry. To be selected for O3b mPOWER is a tremendous validation of ST Engineering iDirect's technology vision and proves that ground infrastructure will play a pivotal role in SES’s ambitious goal to transform satellite service delivery,” said Frederik Simoens, CTO, ST Engineering iDirect. “O3b mPOWER is at the forefront of a significant movement to drive a standards-based, virtualised network approach where ground is in lockstep with space. Through our partnership, we will greatly expand the possibilities for global connectivity.”
“The basis of our O3b mPOWER communications system is defined and advanced by a diverse and robust partner ecosystem. As an industry, we are able to embrace the vision of open networking and seamless satellite services because of like-minded partners such as Gilat and ST Engineering iDirect who understand the step-change in system flexibility and capacity that O3b mPOWER will deliver,” said Stewart Sanders, SES’s Executive Vice President of Technology and O3b mPOWER programme manager. “We have first-hand experience over many years of working with both Gilat and ST Engineering iDirect and have always been impressed with their work as well as what their technologies can provide. Hence, we have full confidence in selecting these two outstanding companies as trusted partners for O3b mPOWER and to deliver a key part of our infrastructure supporting an unparalleled customer experience.”
Focused on making satellites a seamless part of global network solutions, SES has been steadily expanding its O3b mPOWER partner ecosystem. In addition to Gilat and ST Engineering iDirect, SES has also announced O3b mPOWER partnerships with SpaceX for launches, ALCAN, Isotropic Systems and Viasat for customer edge terminals, Amdocs for NFV technology, Kythera Space Solutions for the ARC software, Microsoft for gateways , and IBM and Microsoft for cloud connectivity.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102006117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom